Akebia therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass., may 01, 2025 (globe newswire) -- akebia therapeutics ® , inc. (nasdaq: akba), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted eight newly-hired employees options to purchase an aggregate of 148,000 shares of akebia's common stock on april 30, 2025. the options were granted as an inducement material to each employee entering into employment with akebia. the options were granted in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking